March 27, 2020

Kindly note that during the lockdown SAHPRA Clinical Trials Unit will work remotely with limited number of employees.

The correspondence received by email during the lockdown should be submitted once the situation has stabilised (i.e. once SAHPRA reception is opened).


March 27, 2020

Risk Description:

SAHPRA may be unable to timeously respond to business disruption that could be caused by wide spread of diseases (i.e. COVID 19) and other un-identified continuity threats resulting in management failure to deliver critical entity services to its stake...

March 19, 2020

Dear Industry Partner,

Please note that all information relating to COVID-19 processes and SAHPRA can be found on our website.

See link below

At this stage, SAHPRA is still fully functional and we aim to maintain this stat...

January 29, 2020

We are very excited to announce the launch of our newly designed website.

SAHPRA is transitioning to a new website which is easier to navigate and user-friendly.

As the new website is being loaded, website services may be unavailable for a short period of time.

We apologi...

January 14, 2020


SAHPRA Document for Sales Data Meprobamate-Containing Medicine can be down-loaded here.

The South African Health Products Regulatory Authority is concerned about the potential misuse a...

May 3, 2019

This email serves as an invitation to the ​Workshop between the Regulator and Industry on Clinical Trial related matters.

The workshop will take place on the 31st of May 2019 in Gauteng.

The finalized venue of the meeting will be communicated shortly.

Kindly see the attac...

February 17, 2019

Dear All,

Find below the various contact numbers at the SAHPRA Inspectorate and Law Enforcement Unit:

Licensing  Pharma:  012 842  7584
Site Master File Inspectorate: 012 842  7584

CPP & GMP Certificate: 012 842 7577

Permits Law Enforcement: 012 842 7579

Names & Sc...

Please reload

© 2020 by SACRA. Proudly created with


  • White LinkedIn Icon
  • Facebook Clean
  • Twitter Clean